Health Dictionary Find a Doctor

Peptic ulcer

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Synonyms and keywords: Gastroduodenal ulcers; Peptic ulceration; gastric ulcer; duodenal ulcer.

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

Peptic ulcer disease is a defect in muscularis mucosa of gastrointestinal tract. Peptic ulcer is classified into 2 depending upon the location of ulcer, gastric ulcer and duodenal ulcer. The most common cause of peptic ulcer disease is H.pylori infection which is acquired in childhood but presents in adulthood. Other causes of peptic ulcer disease are chronic use of NSAID, family history of peptic ulcer disease. Persistant use of NSAIDS or chronic infection with H.Pylori results in inflammation of antral mucosa and ultimately causes the ulcer. The most common symptoms of peptic ulcer disease include episodic epigastric pain, heartburn, loss of appettite, gastroesophageal reflux, waterbrash, hematemesis and melena. Common physical examination findings of peptic ulcer disease include epigastric tenderness, tachycardia. Endoscopy is the gold standard test for the diagnosis of the peptic ulcer disease. Treatment of helicobacter pylori with antimicrobial agents is indicated for patients with gastric or duodenal ulceration. Pharmacologic therapies for peptic ulcer disease due to H. pylori is either triple or quadruple pharmacologic agents that include a Proton pump inhibitors plus a combination of antimicrobial agents.

Historical Perspective

Hundred years ago, Polish clinical researcher, professor W.Jaworski was the first to describe the spiral-shaped microorganism at Cracow Jagiellonian University but it was later confirmed in the animal by G.Bizzazero. Asklepios was the first to describe an association between GI bleeding and peptic ulcer disease. In 1982 Warren and B.J marshall cultured the organism and found a strong association between Helicobacter pylori and inflammation of gastric mucosa, not due to spicy food and stress and were awarded the noble prize.

Classification

Peptic ulcer disease may be classified into two types based on the location, gastric ulcer and duodenal ulcer. Gastric ulcers are present mostly at lesser curvature of the stomach. Duodenal ulcers are mostly present at the duodenal bulb.

Pathophysiology

A major causative factor (60% of gastric and 90% of duodenal ulcers) is chronic inflammation due to Helicobacter pylori that colonize the antral mucosa. The immune system is unable to clear the infection, despite the appearance of antibodies. Thus, the bacterium can cause a chronic active gastritis (type B gastritis), resulting in a defect in the regulation of gastrin production. Excess Gastrin stimulates the production of gastric acid by parietal cells. The acid erodes the mucosa and causes the ulcer. Another major cause of PUD is the use of NSAIDs. The gastric mucosa protects itself from gastric acid with a layer of mucus, the secretion of which is stimulated by certain prostaglandins. NSAIDs block the activity of cyclooxygenase 1 (cox-1), which is essential for the production of these prostaglandins.

Causes

Common causes of peptic ulcer disease include Helicobacter pylori infection and NSAID use. Less common causes of peptic ulcer disease include Crohn’s disease, Zollinger-Ellison syndrome, Cushing and Curling ulcers, Carcinoid tumors, and carcinoid syndrome.

Differentiating Peptic ulcer overview from Other Diseases

Peptic ulcer disease must be differentiated from other causes of acute upper gastrointestinal bleeding such as esophageal varices, Mallory-Weiss syndrome, gastrointestinal cancer, arteriovenous malformations, esophagitis, and esophageal ulcer. Peptic ulcer disease must also be differentiated from gastroesophageal reflux disease (GERD,pancreatitis, Zollinger-Ellison Syndrome, Cholelithiasis, gastric outlet syndrome, myocardial infarction ,pleural empyema and appendicitis.

Epidemiology and Demographics

The incidence and prevalence of Helicobacter pylori infection are generally higher among people born outside North America. Within North America, the prevalence of the infection is higher in certain racial and ethnic groups, and people who have immigrated to North America. Peptic ulcer disease is acquired during childhood.The incidence of Peptic ulcer disease increases with age; the median age at diagnosis is 18-30 years. Peptic ulcer disease affect equally in childhood. Men are more commonly affected by peptic ulcer disease than women in adulthood.

Risk Factors

Common risk factors in the development of peptic ulcer disease include infection from Helicobacter pylori, chronic use of NSAIDs, cigarette smoking, alcohol intake, family history of peptic ulcer, and age >50 years. Less common risk factors in the development of peptic ulcer disease include psychological stress, nosocomial stress ulcers, and coagulopathy. Rare conditions associated with gastric acid hypersecretion, such as zollinger-ellison syndrome, mastocytosis, or a retained antrum following partial gastrectomy gastrinoma or multiple endocrine neoplasia types I (MEN-I), antral G cell hyperplasia, basophilic leukemias, short bowel syndrome.

Screening

According to the American Society of Gastroenterology, screening for the Peptic Ulcer Disease is not recommended.

Natural History, Complications, and Prognosis

Natural History

The infection of Helicobacter pylori, a common cause of peptic ulcer disease is acquired usually during the childhood but presents in second to the fifth decade of life.Patient presents with episodic epigastric pain, indigestion, bloating, hematemesis and melena. Peptic ulcers tend to come back if untreated.

Complications

Peptic ulcer disease if not treated, the patient can develop complications like bleeding, perforation, obstruction, stricture.Chronic infection of Helicobacter pylori leads to gastric cancer, MALT lymphoma, Iron deficiency anemia, Idiopathic thrombocytopenic purpura.

Prognosis

Prognosis is good if the eradication therapy of Helicobacter pylori is taken.The recurrence rate of patients with peptic ulcer disease is less than 20%.

Diagnosis

Diagnostic Study of choice

Endoscopy is the gold standard test for the diagnosis of the peptic ulcer disease.

History and Symptoms

The hallmark of peptic ulcer disease is an episodic epigastric pain which cause awakening at night.A positive history of epigastric pain, use of drugs like NSAIDs including aspirin which inhibit cyclooxygenase, use of antiplatelets, steroids and family history of peptic ulcer disease is suggestive of peptic ulcer disease. The most common symptoms of peptic ulcer disease include episodic epigastric pain, heartburn, loss of appettite, gastroesophageal reflux, waterbrash, hematemesis and melena. Less common symptoms of peptic ulcer disease include intolerance to fatty food.

Physical Examination

Peptic ulcer disease patient appears in severe stress due to abdominal pain. Common physical examination findings of peptic ulcer disease include epigastric tenderness, tachycardia.Perforated peptic ulcer disease patient presents with classic triad of severe epigastric tenderness, tachycardia and abdominal rigidity. Clinical signs of perforated peptic ulcer comes in 3 stages: In the initial stage within first 2 hours, the patient presents with tachycardia, epigastric pain and cool extremities. In next 2 to 12 hours, the patient presents with lower right quadrant tenderness and abdominal rigidity. In more than 12 hours, the patient presents with abdominal distension, hypotension, and pyrexia with acute circulatory collapse.

Laboratory Findings

There is no specific diagnostic laboratory test for peptic ulcer disease but in the patient with the history of peptic ulcer disease, the laboratory test is used to rule out bleeding and to document the status of eradication therapy and to test refractory ulcers.

Imaging Findings

If a peptic ulcer perforates, air will leak from the inside of the gastrointestinal tract (which always contains some air) to the peritoneal cavity (which normally never contains air). This leads to “free gas” within the peritoneal cavity. If the patient stands erect, as when having a chest X-ray, the gas will float to a position underneath the diaphragm. Therefore, gas in the peritoneal cavity, shown on an erect chest X-ray or supine lateral abdominal X-ray, is an omen of perforated peptic ulcer disease. An esophagogastroduodenoscopy (EGD), a form of endoscopy, also known as a gastroscopy, is carried out on patients in whom a peptic ulcer is suspected. By direct visual identification, the location and severity of an ulcer can be described. Moreover, if no ulcer is present, EGD can often provide an alternative diagnosis.

Other diagnostic studies

Testing of H.pylori infection is very important for treating ulcers. H.pylori tested by 2 methods : invasive and non-invasive. Rapid urease testing is invasive test which is used as diagnostic study of choice. Stool monoclonal antigen test is one of the non-invasive test which is used to diagnose active infection.

Treatment

Medical Therapy

Peptic ulcer disease is the cause of dyspepsia in about 10% of patients. 95% of duodenal and 70% of gastric ulcers are associated with Helicobacter pylori. Eradication of Helicobacter pylori with antimicrobial agents is indicated for patients with gastric or duodenal peptic ulceration, who are colonized with H. pylori, and patients with MALT lymphoma. Eradication therapy should also be considered in patients with immune thrombocytopenic purpura who are H. pylori-positive and patients who have undergone resection for early-stage gastric cancer. Pharmacologic therapies for peptic ulcer disease due to H. pylori is either triple or quadruple pharmacologic agents that include a Proton pump inhibitors plus a combination of antimicrobial agents. The use of antimicrobial therapy is discouraged among asymptomatic carriers.

Surgery

Surgery for peptic ulcer is indicated for bleeding and perforated peptic ulcer.Bleeding ulcers are usually treated first with endoscopic therapy but if they bleed after endoscopic therapy, surgery is done to control bleeding. Perforated peptic ulcer is an emergency, immediate laparoscopic closure of ulcer is done.

Prevention

Helicobacter pylori eradication has been proved as the most cost-effective strategy for primary prevention of NSAID-associated peptic ulcer, especially for patients above the age of 50 years.

References

Template:WikiDoc Sources

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

Hundred years ago, polish clinical researcher professor W.Jaworski was the first to describe spiral-shaped microorganism at Cracow Jagiellonian University. Asklepios was the first to describe an association between GI bleeding and peptic ulcer disease. In 1982 Warren and B.J marshall cultured the organism and found a strong association between Helicobacter pylori and inflammation of gastric mucosa and were awarded the noble prize.

Historical Perspective

Discovery

  • Hundred years ago, polish clinical researcher professor W.Jaworski was the first to describe the spiral-shaped microorganism at Cracow Jagiellonian University
  • In pre-16th century:
  • In 1586, Marcellus Donatus of Mantua described gastric ulcers by performing autopsies
  • In 1688, Johannes von Murault gave detailed description of duodenal ulcers
  • In 1812, Broussais found that if acute gastritis is untreated, it can lead to chronic gastritis
  • In 1821, Nepveu found a relationship between gastritis and gastric cancer
  • In 1857, William Brintonin described ulcer of the stomach and gastric cancer in his book
  • In 1875, G.Bottcher and M. Letulle hypothesize that ulcers are caused by bacteria
  • In 1880, J.Cohnheim found that ulcers may be caused by chemical factors
  • In 1889, Walery Jaworski found spiral organisms in sediment washings of humans and proposed that these organisms may be involved with gastric disease
  • In 1910, Moynihan wrote a book on duodenal ulcer[2]
  • In 1971, Howard Steer found H. pylori from biopsies of a patient with ulcers[3][4]
  • In late 1970, J.R Warren, a pathologist in Perth, Australia found the appearance of spiral bacteria overlying gastric mucosa[4][5]
  • In 1982 , Warren and B.J marshall cultured the organism and found a strong association between Helicobacter pylori and inflammation of gastric mucosa[4][5]
  • In an act of self-experimentation Marshall drank a petri-dish containing a culture of organisms extracted from a patient and soon developed gastritis. His symptoms disappeared after two weeks, but he took antibiotics to kill the remaining bacteria at the urging of his wife.This experiment was published in 1984 in the Australian Medical Journal[6]
  • In 1994, Parsonnet et al found an association between H. pylori and lymphomas of the gastrointestinal tract[7]
  • In 1997 Tomb et al. completed sequencing of the entire 1,667,867 base pairs of the H. pylori genome. This helped in identifying new virulence factors for the infectivity of H. pylori at the molecular level[8]
  • In 2001, Chan et al. showed that eradication of H. pylori prevents bleeding from ulcers that is caused by aspirin and non-steroidal anti-inflammatory drugs[9]
  • In 2002, European Helicobacter Pylori Study Group published the Maastricht 2-2000 Consensus Report, found a “test-and-treat” strategy for H. pylori in young patients without atypical symptoms. It suggests the use of noninvasive testing to evaluate for H. pylori [10]
  • In 2005 Warren and Marshall awarded the Nobel Prize in Physiology or Medicine by Karolinska Institute in Stockholm for their discovery of the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer disease[11]
  • In 1992,Covacci discovered CagA gene, which encodes for a cytotoxin-associated surface protein, related with strains of H. pylori that caused duodenal ulcers and was discovered by molecular techniques were first involved in the pathogenesis of peptic ulcer disease [12]

Landmark Events in the Development of Treatment Strategies

References

  1. Kidd M, Modlin IM (1998). “A century of Helicobacter pylori: paradigms lost-paradigms regained”. Digestion. 59 (1): 1–15. PMID 9468093.
  2. Barry, J (2002). Helicobacter pioneers : firsthand accounts from the scientists who discovered helicobacters, 1892-1982. Victoria, Australia Malden, MA, USA: Blackwell. ISBN 0867930357.
  3. Barry, J (2002). Helicobacter pioneers : firsthand accounts from the scientists who discovered helicobacters, 1892-1982. Victoria, Australia Malden, MA, USA: Blackwell. ISBN 0867930357.
  4. 4.0 4.1 4.2 Konturek JW (2003). “Discovery by Jaworski of Helicobacter pylori and its pathogenetic role in peptic ulcer, gastritis and gastric cancer”. J. Physiol. Pharmacol. 54 Suppl 3: 23–41. PMID 15075463.
  5. 5.0 5.1 “Home | CDC Ulcer”.
  6. {{cite web url=http://www.mja.com.au/public/issues/183_11_051205/van11000_fm.html#0_i1091639| title=Research Enterprise, The 2005 Nobel Prize in Physiology or Medicine |accessdate=2007-08-26}}
  7. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD (1994). “Helicobacter pylori infection and gastric lymphoma”. N. Engl. J. Med. 330 (18): 1267–71. doi:10.1056/NEJM199405053301803. PMID 8145781.
  8. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, Peterson S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, McKenney K, Fitzegerald LM, Lee N, Adams MD, Hickey EK, Berg DE, Gocayne JD, Utterback TR, Peterson JD, Kelley JM, Cotton MD, Weidman JM, Fujii C, Bowman C, Watthey L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, Fraser CM, Venter JC (1997). “The complete genome sequence of the gastric pathogen Helicobacter pylori”. Nature. 388 (6642): 539–47. doi:10.1038/41483. PMID 9252185.
  9. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK, Wu JC, Lau JY, Hui Y, Lai MS, Chan HL, Sung JJ (2001). “Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen”. N. Engl. J. Med. 344 (13): 967–73. doi:10.1056/NEJM200103293441304. PMID 11274623.
  10. 10.0 10.1 Malfertheiner P, Mégraud F, O’Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G (2002). “Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report”. Aliment. Pharmacol. Ther. 16 (2): 167–80. PMID 11860399.
  11. “The Nobel Prize in Physiology or Medicine 2005”.
  12. Covacci A, Censini S, Bugnoli M, Petracca R, Burroni D, Macchia G, Massone A, Papini E, Xiang Z, Figura N (1993). “Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer”. Proc. Natl. Acad. Sci. U.S.A. 90 (12): 5791–5. PMC 46808. PMID 8516329.
  13. Buckley MJ, O’Morain CA (1998). “Helicobacter biology–discovery”. Br. Med. Bull. 54 (1): 7–16. PMID 9604426.
  14. Barry, J (2002). Helicobacter pioneers : firsthand accounts from the scientists who discovered helicobacters, 1892-1982. Victoria, Australia Malden, MA, USA: Blackwell. ISBN 0867930357.
  15. Dintzis RZ, Hastings AB (1953). “The Effect of Antibiotics on Urea Breakdown in Mice”. Proc. Natl. Acad. Sci. U.S.A. 39 (7): 571–8. PMC 1063826. PMID 16589306.
  16. LIEBER CS, LEFEVRE A (1957). “[Effect of oxytetracycline on acidity, ammonia, and urea in gastric juice in normal and uremic subjects]”. C. R. Seances Soc. Biol. Fil. (in French). 151 (5): 1038–42. PMID 13500735.
  17. “HELIDAC® Therapy”.
  18. Rauws EA, Tytgat GN (1990). “Cure of duodenal ulcer associated with eradication of Helicobacter pylori”. Lancet. 335 (8700): 1233–5. PMID 1971318.
  19. Becx MC, Janssen AJ, Clasener HA, de Koning RW (1990). “Metronidazole-resistant Helicobacter pylori”. Lancet. 335 (8688): 539–40. PMID 1968548.
  20. Ulcer, Diagnosis and Treatment – CDC Bacterial, Mycotic Diseases

Template:WikiDoc Sources

Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

Peptic ulcer disease may be classified into two types based on the location within the gastrointestinal tract. gastric ulcer and duodenal ulcer. Gastric ulcers are present mostly at lesser curvature of the stomach while Duodenal ulcers are mostly present at the duodenal bulb.

Classification

Peptic ulcer

Peptic ulcer disease may be classified according to location into two subtypes: [1][2]

Classification and prevalences of stigmata of recent hemorrhage of peptic ulcer using endoscopy

Classification and prevalences of stigmata of recent hemorrhage of peptic ulcer using endoscopy*
Stigmata of hemorrhage Forrest classification Prevalence
Active spurting bleeding IA 12%(spurting+oozing)
Active oozing bleeding IB
Non-bleeding visible vessel IIA 8%
Adherent clot IIB 8%
Flat pigmented spot IIC 16%
Clean base III 55%

*Adopted:American college of gasteroenterology[3]

Gastric ulcer

Gastric ulcer is further divided on the basis of location and endoscopic findings:

Johnson classification

  • Gastric ulcer is further classified into 3 subtypes depending upon their location:[4][5][6]
    • Type 1: Ulcer present at the body of stomach without involving duodenum, pylorus or prepyloric region and not associated with hypersecretion of gastric acid
    • Type 2: Ulcer present at the body of stomach combined with duodenum and associated with gastric acid hypersecretion
    • Type 3: Ulcer close to pylorus and associated with gastric acid hypersecretion

Sakita classification

  • Gastric ulcer classification by using endoscopic staging system of Sakita into three stages:[7]
    • Active
    • Healing
    • Scarring
ACTIVE STAGE
A1 Surrounding mucosa is found to be edematously swollen and there is no regenerating epithelium seen on endoscopy
A2 Surrounding mucosa is less edematous, a small amount of regenerating epithelium is seen at the ulcer margin

A red halo in the marginal zone, a white slough circle and converging mucosal folds t the ulcer margin are frequently seen

HEALING STAGE
H1 The white coating is becoming thin and the regenerating epithelium is extending into the ulcer base

The gradient between the ulcer margin and the ulcer floor is becoming flat

The ulcer crater is still evident and the margin of the ulcer is sharp

The diameter of the mucosal defect is about one-half to two thirds that of A1

H2 The defect is smaller than in H1 and the regenerating epithelium covers most of the ulcer floor. The area of white coating is about a quarter to one-third that of A1
SCARRING STAGE
S1 The regenerating epithelium completely covers the floor of the ulcer

The white coating has disappeared

Initially, the regenerating region is markedly red but upon close observation, many capillaries can be seen and this is called ‘‘red scar’’

S2 In several months to a few years, the redness is reduced to the color of the surrounding mucosa and this is called ‘‘white scar’’

References

  1. Belousov AS, Rakitskaia LG, Mamedova LD, Zhakov VP (1989). “[Pathogenesis and classification of peptic ulcer]”. Vrach Delo (3): 70–3. PMID 2750129.
  2. Tytgat GN (2011). “Etiopathogenetic principles and peptic ulcer disease classification”. Dig Dis. 29 (5): 454–8. doi:10.1159/000331520. PMID 22095009.
  3. “Management of Patients with Ulcer Bleeding | American College of Gastroenterology”.
  4. Johnson HD (1965). “Gastric ulcer: classification, blood group characteristics, secretion patterns and pathogenesis”. Ann. Surg. 162 (6): 996–1004. PMC 1477018. PMID 5845595.
  5. BARON JH (1963). “AN ASSESSMENT OF THE AUGMENTED HISTAMINE TEST IN THE DIAGNOSIS OF PEPTIC ULCER. CORRELATIONS BETWEEN GASTRIC SECRETION, AGE AND SEX OF PATIENTS, AND SITE AND NATURE OF THE ULCER”. Gut. 4: 243–53. PMC 1413442. PMID 14058266.
  6. JOHNSON HD (1955). “The special significance of concomitant gastric and duodenal ulcers”. Lancet. 268 (6858): 266–70. PMID 13234346.
  7. Kaneko E, Hoshihara Y, Sakaki N, Harasawa S, Ashida K, Asaka M; et al. (2000). “Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor”. J Gastroenterol. 35 (11): 824–31. PMID 11085491.

Template:WikiDoc Sources

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

A major causative factor (60% of gastric and 90% of duodenal ulcers) is chronic inflammation due to Helicobacter pylori that colonize the antral mucosa. The immune system is unable to clear the infection, despite the appearance of antibodies. Thus, the bacterium can cause a chronic active gastritis known as type B gastritis. This results in a defect in gastrin production leading to increasedgastrin secretion. Gastrin stimulates the production of gastric acid by the parietal cells. The acid erodes the mucosa and causes the ulcer. Another major cause of peptic ulcer disease is the chronic use of NSAIDs The gastric mucosa protects itself from gastric acid with a layer of mucus, the secretion of which is stimulated by certain prostaglandins. NSAIDs block the function of cyclooxygenase 1 (cox-1), which is essential for the production of these prostaglandins.

Pathophysiology

Peptic ulcer occurs due to distruption of muscularis mucosa which is required in the maintenance of the integrity of the gastric mucosa

Defensive mechanism of gastric mucosa

Mucosal barrier consists of three protective components which include:[1][2][3][4]

Diagram of alkaline Mucous layer in stomach with mucosal defense mechanisms
Source:Wikimedia Commons [5]

The two most important etiological factors in the development of PUD are:[6][7][8]

Role of Helicobacter pylori

Penetration

Factors that help in penetration and growth of Helicobacter pylori are:[9][10]

Colonzation:

  • The colonization of virulent CagA-positive Helicobacter pylori strains leads to the degeneration of surface epithelial cells
  • This degeneration results in increased exfoliation of surface epithelial cells
  • The exfoliation mediated compensatory cell proliferation leads to the movement of immature cells to the foveolae and surface
  • Immature cells leads to impaired mucin and bicarbonate production and the integrity of the mucous barrier may be compromised
  • All of above factors lead to activation of complement via the alternative pathway and the release of chemical mediators by mast cells and activated polymorphs may lead to microvascular disturbances and focal ischemic damage to the surface epithelium
  • Helicobacter pylori infection down-regulates E-cadherin expression in gastric epithelial cells which affect the resistance of the mucosa to acid attack
  • Decreased mucus production, release of chemical mediators and down-regulation of E- cadherin leads to mucosal damage leads to ulcer formation[11][12][13]

Immunological response

Factors responsible for immunological response of Helicobacter pylori are :

 
 
 
 
 
 
 
 
Helicobacter pylori infection
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inflammatory response
secretes IL-8 ,IL-1b
 
 
 
 
Production of
alkaline ammonia
 
 
 
 
Production of urease
bacterial phospholipase A
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Infux ofneutophilsandmacrophages
release of lysosomal enzymes
leukotrienes (LT)and
reactive oxygen
 
 
 
 
Inhibition of D-cells
leads to inappropriate release of somatostatin
and hypergastrinemia
 
 
 
 
Production of urease
,phospholipase
A and C
release toxic metabolities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mucosal injury
 
 
 
 
 

Role of Helicobacter pylori in causing gastric ulcer

  • Factors responsible for ulcer formation:[21]
  • There is decrease in acid and decrease in parietal cell volume which further predisposes to development to ulcer formation.[13]

Role of Helicobacter pylori in causing duodenal ulcer

Role of NSAIDS

 
 
 
 
 
 
 
 
NSAIDs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COX-1 inhibitor
 
 
 
 
Topical irritation
 
 
 
 
COX-2 inhibitor
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Decreased blood flow
 
 
 
 
Epithelial damage
 
 
 
 
Inhibit
leucocyte adhesion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mucosal injury
 
 
 
 
 
 

Other factors

Other factors responsible for peptic ulcer disease:

Smoking

  • Chronic smoking leads to mucosal damage or deals healing of ulcer by following mechanism:[30]

Severe stress

Genetics

Associated Conditions

Gross Pathology

  • Gastric ulcers are most often localized on the lesser curvature of the stomach
  • Duodenal ulcers are more located at bulb of duodenum
  • Characteristic findings of a peptic ulcer on gross pathology include:
    • Round to oval
    • Two to four cm diameter
    • Smooth base with perpendicular borders.
    • Parietal scarring with radial folds may be evident in the surrounding mucosa

Microscopic Pathology

  • A peptic ulcer is a mucosal defect produced by acid-pepsin aggression which penetrates the muscularis mucosae and muscularis propria
  • There is increased plasma cells, neutrophilic infiltrate, villous blunting
  • The surface epithelium usually shows mucous cell (pseudopyloric) metaplasia
  • During the active phase, the base of the ulcer shows 4 zones:
    • Inflammatory exudate: polymorphonuclear infiltration which along with bacterial products stimulate the production of IL-8 and tumor necrosis factor alpha (TNF-α) and IL-1 released by macrophages in response to bacterial lipopolysaccharide
    • Fibrinoid necrosis
    • Granulation tissue
    • Fibrous tissue. The fibrous base of the ulcer may contain vessels with thickened wall or with thrombosis[38]

References

  1. Butler BD, Lichtenberger LM |title=Gastric mucosal barrier: hydrophobic lining to the lumen of the stomach |journal=Am. J. Physiol. |volume=244 |issue=5 |pages=G561–8 |year=1983 |pmid=6846549 |doi= |url=}}
  2. Clamp JR, Ene D (1989). “The gastric mucosal barrier”. Methods Find Exp Clin Pharmacol. 11 Suppl 1: 19–25. PMID 2657286.
  3. Werther JL (2000). “The gastric mucosal barrier”. Mt. Sinai J. Med. 67 (1): 41–53. PMID 10677782.
  4. Forssell H (1988). “Gastric mucosal defence mechanisms: a brief review”. Scand. J. Gastroenterol. Suppl. 155: 23–8. PMID 3072665.
  5. By M•Komorniczak(http://creativecommons.org/licenses/by/3.0)
  6. url=http://www.nejm.org/doi/full/10.1056/NEJM199003293221307 |title=Pathogenesis of Peptic Ulcer and Implications for Therapy — NEJM |format= |work= |accessdate=}}
  7. 7.0 7.1 “Pathogenesis of Peptic Ulcer and Implications for Therapy — NEJM”.
  8. Hawkey CJ (1999). “Personal review: Helicobacter pylori, NSAIDs and cognitive dissonance”. Aliment. Pharmacol. Ther. 13 (6): 695–702. PMID 10383497.
  9. Kusters JG, van Vliet AH, Kuipers EJ (2006). “Pathogenesis of Helicobacter pylori infection”. Clin. Microbiol. Rev. 19 (3): 449–90. doi:10.1128/CMR.00054-05. PMC 1539101. PMID 16847081.
  10. Huang JQ, Sridhar S, Hunt RH (2002). “Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis”. Lancet. 359 (9300): 14–22. doi:10.1016/S0140-6736(02)07273-2. PMID 11809181.
  11. Kim JS, Jung HC, Kim JM, Song IS, Kim CY (1998). “Interleukin-8 expression by human neutrophils activated by Helicobacter pylori soluble proteins”. Scand. J. Gastroenterol. 33 (12): 1249–55. PMID 9930387.
  12. Kimura K (1972). “Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach”. Gastroenterology. 63 (4): 584–92. PMID 5077145.
  13. 13.0 13.1 Malaty HM, Graham DY, Isaksson I, Engstrand L, Pedersen NL (2000). “Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection?”. Arch. Intern. Med. 160 (1): 105–9. PMID 10632311.
  14. url=http://www.nejm.org/doi/full/10.1056/NEJM199003293221307 |title=Pathogenesis of Peptic Ulcer and Implications for Therapy — NEJM |format= |work= |accessdate=}}
  15. Logan RP (1996). “Adherence of Helicobacter pylori”. Aliment. Pharmacol. Ther. 10 Suppl 1: 3–15. PMID 8730255.
  16. Crabtree JE (1996). “Gastric mucosal inflammatory responses to Helicobacter pylori”. Aliment. Pharmacol. Ther. 10 Suppl 1: 29–37. PMID 8730257.
  17. Ernst PB, Jin Y, Reyes VE, Crowe SE (1994). “The role of the local immune response in the pathogenesis of peptic ulcer formation”. Scand. J. Gastroenterol. Suppl. 205: 22–8. PMID 7863238.
  18. Mobley HL (1996). “The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration”. Aliment. Pharmacol. Ther. 10 Suppl 1: 57–64. PMID 8730260.
  19. Nilius M, Malfertheiner P (1996). “Helicobacter pylori enzymes”. Aliment. Pharmacol. Ther. 10 Suppl 1: 65–71. PMID 8730261.
  20. Slomiany BL, Kasinathan C, Slomiany A (1989). “Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol)”. Am. J. Gastroenterol. 84 (10): 1273–7. PMID 2801678.
  21. Sipponen P, Varis K, Fräki O, Korri UM, Seppälä K, Siurala M (1990). “Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients”. Scand. J. Gastroenterol. 25 (10): 966–73. PMID 2263883.
  22. Wyatt JI, Rathbone BJ, Dixon MF, Heatley RV (1987). “Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis”. J. Clin. Pathol. 40 (8): 841–8. PMC 1141122. PMID 3654985.
  23. el-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE (1995). “Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease”. Gastroenterology. 109 (3): 681–91. PMID 7657096.
  24. el-Omar E, Penman I, Dorrian CA, Ardill JE, McColl KE (1993). “Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer”. Gut. 34 (8): 1060–5. PMC 1374354. PMID 8174954.
  25. el-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE (1995). “Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease”. Gastroenterology. 109 (3): 681–91. PMID 7657096.
  26. el-Omar E, Penman I, Dorrian CA, Ardill JE, McColl KE (1993). “Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer”. Gut. 34 (8): 1060–5. PMC 1374354. PMID 8174954.
  27. Borody TJ, George LL, Brandl S, Andrews P, Ostapowicz N, Hyland L, Devine M (1991). “Helicobacter pylori-negative duodenal ulcer”. Am. J. Gastroenterol. 86 (9): 1154–7. PMID 1882793.
  28. Huang JQ, Sridhar S, Hunt RH (2002). “Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis”. Lancet. 359 (9300): 14–22. doi:10.1016/S0140-6736(02)07273-2. PMID 11809181.
  29. Holvoet J, Terriere L, Van Hee W, Verbist L, Fierens E, Hautekeete ML (1991). “Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study”. Gut. 32 (7): 730–4. PMC 1378985. PMID 1855677.
  30. Müller-Lissner SA (1986). “Bile reflux is increased in cigarette smokers”. Gastroenterology. 90 (5 Pt 1): 1205–9. PMID 3956939.
  31. Räihä I, Kemppainen H, Kaprio J, Koskenvuo M, Sourander L (1998). “Lifestyle, stress, and genes in peptic ulcer disease: a nationwide twin cohort study”. Arch. Intern. Med. 158 (7): 698–704. PMID 9554675.
  32. FakhreYaseri H, Shakaraby M, Bradaran HR, Soltani Arabshahi SK, Fakhre Yaseri AM (2014). “CagA and VacA genotypes in peptic ulcer disease and non-ulcer dyspepsia: a case-control study”. Med J Islam Repub Iran. 28: 104. PMC 4301206. PMID 25664305.
  33. Jung DH, Kim JH, Chung HS, Park JC, Shin SK, Lee SK, Lee YC (2015). “Helicobacter pylori Eradication on the Prevention of Metachronous Lesions after Endoscopic Resection of Gastric Neoplasm: A Meta-Analysis”. PLoS ONE. 10 (4): e0124725. doi:10.1371/journal.pone.0124725. PMC 4411104. PMID 25915048.
  34. Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, Tari A, Kitadai Y, Matsumoto H, Nagaya T, Kamoshida T, Watanabe N, Chiba T, Origasa H, Asaka M (2012). “Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan”. Gut. 61 (4): 507–13. doi:10.1136/gutjnl-2011-300495. PMID 21890816.
  35. {{cite journal |vauthors=Suzuki T, Matsushima M, Masui A, Watanabe K, Takagi A, Ogawa Y, Shirai T, Mine T |title=Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial |journal=Am. J. Gastroenterol. |volume=100 |issue=6 |pages=1265–70 |year=2005 <ref name=”pmid18945961″>Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel JB (2009). “Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review”. Blood. 113 (6): 1231–40. doi:10.1182/blood-2008-07-167155. PMID 18945961.
  36. {{cite journal |vauthors=Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA |title=The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia |journal=Blood |volume=117 |issue=16 |pages=4190–207 |year=2011 |
  37. name=”urlAmerican Journal of Gastroenterology – ACG Clinical Guideline: Treatment of Helicobacter pylori Infection”>“American Journal of Gastroenterology – ACG Clinical Guideline: Treatment of Helicobacter pylori Infection”.
  38. “ATLAS OF PATHOLOGY”. Retrieved 2007-08-26.

Template:WikiDoc Sources

Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

Common causes of peptic ulcer disease include Helicobacter pylori infection and NSAID use. Less common causes of peptic ulcer disease include Crohn’s disease, Zollinger-Ellison syndrome, Cushing and Curling ulcers, Carcinoid tumors, and carcinoid syndrome.

Causes

Common Causes[1][2][3]

Less common causes

Rare causes of peptic ulcer disease

Genetic causes[4]

Causes by Organ System

Cardiovascular No underlying causes
Chemical / poisoning No underlying causes
Dermatologic Rosacea,Chronic idiopathic urticaria ,Psoriasis vulgaris ,Behcet’s disease ,Alopecia areata,Sweet’s syndrome [5]
Drug Side Effect Aceclofenac, Acemetacin, Alendronate, Artemether and lumefantrin, Aspirin, Azapropazone, Benoxaprofen, Bisphosphonates, Carbinoxamine, Celecoxib, Clopidogrel, Dexamethasone, Diclofenac, Diflunisal, Ethanol, ethanolamine oleate, Etidronic acid, Etodolac, Etoricoxib, Febuxostat, Fenbufen, Fenoprofen, Flurbiprofen, Glucocorticoids, Hydrocortisone, Ibuprofen, Indomethacin, Ketoprofen, Laxative abuse, Mefenamic acid, Meloxicam, Mepenzolate bromide, Methylprednisolone, Nabumetone, Naproxen, Naproxen and esomeprazole magnesium, Niacin, Non steroidal anti-inflammatory drugs, Oxcarbazepine, Para-amino salicylic acid, Pergolide, Phenylbutazone, Pramipexole, Piroxicam, Pramipexole, Prednisolone, Prednisone, Rofecoxib, Sertraline, Sulindac, Tacrolimus, Tenoxicam, Tiaprofenic acid, Tocilizumab, Tolazoline, Tolmetin, Trimetrexate
Ear Nose Throat No underlying causes
Endocrine Cushing syndrome, Multiple endocrine neoplasia type 1, Zollinger-Ellison syndrome, primary hyperparathyroidism
Environmental No underlying causes
Gastroenterologic Crohn disease, Cushing ulcers, Dieulafoy’s lesion, Duodenal ulcer, Eosinophilic gastroenteritis, Gastric ulcer, Oesophagitis, Zollinger-Ellison syndrome, Carcinoid tumours and carcinoid syndrome, Stomach cancer, Curling ulcers
Genetic Zollinger -Ellison syndrome associated with MEN TYPE 1 syndrome caused by mutation in MEN gene present on chromosome 11q 13
Hematologic Mastocytosis, Polycythaemia rubra vera, Primary thrombocythemia
Iatrogenic Mechanical ventilation
Infectious Disease Helicobacter pylori
Musculoskeletal / Ortho No underlying causes
Neurologic Cushing ulcers
Nutritional / Metabolic Hypercalcaemia
Obstetric/Gynecologic No underlying causes
Oncologic Carcinoid tumours and carcinoid syndrome, Stomach cancer, Zollinger-Ellison syndrome , gastrinomas
Opthalmologic No underlying causes
Overdose / Toxicity Aceclofenac, Acemetacin, Alendronate, Aspirin, Azapropazone, Benoxaprofen, Bisphosphonates, Celecoxib, Clopidogrel, Diclofenac, Diflunisal, Ethanol, Etodolac, Etoricoxib, Fenbufen, Fenoprofen, Flurbiprofen, Glucocorticoids, Ibuprofen, Indomethacin, Ketoprofen, Laxative abuse, Mefenamic acid, Meloxicam, Nabumetone, Naproxen, Non steroidal anti-inflammatory drugs, Para-amino salicylic acid, Phenylbutazone, Piroxicam, Prednisolone, Rofecoxib, Sulindac, Tacrolimus, Tenoxicam, Tiaprofenic acid, Tolazoline, Trimetrexate
Psychiatric Curling ulcers
Pulmonary Sarcoidosis
Renal / Electrolyte Hypercalcemia
Rheum / Immune / Allergy Fibromyalgia[6]
Sexual No underlying causes
Trauma Burns
Urologic No underlying causes
Dental No underlying causes
Miscellaneous Alcohol, Caffeine, Smoking

Causes in Alphabetical Order


References

  1. Malfertheiner P, Chan FK, McColl KE (2009). “Peptic ulcer disease”. Lancet. 374 (9699): 1449–61. doi:10.1016/S0140-6736(09)60938-7. PMID 19683340.
  2. Hirschowitz BI, Lanas A (2002). “Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse”. J. Clin. Gastroenterol. 34 (5): 523–8. PMID 11960062.
  3. Dovjak P (2017). “[Duodenal ulcers, gastric ulcers and Helicobacter pylori]”. Z Gerontol Geriatr (in German). 50 (2): 159–169. doi:10.1007/s00391-017-1190-x. PMID 28150170.
  4. Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, Lewington V; et al. (2006). “Gastrinoma (duodenal and pancreatic)”. Neuroendocrinology. 84 (3): 173–82. doi:10.1159/000098009. PMID 17312377.
  5. Kutlubay Z, Zara T, Engin B, Serdaroğlu S, Tüzün Y, Yilmaz E; et al. (2014). “Helicobacter pylori infection and skin disorders”. Hong Kong Med J. 20 (4): 317–24. doi:10.12809/hkmj134174. PMID 25045884.
  6. Invalid <ref> tag; no text was provided for refs named pmid28384332

Template:WikiDoc Sources

Differentiating Peptic ulcer from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Guillermo Rodriguez Nava, M.D. [2] Manpreet Kaur, MD [3]

Overview

Peptic ulcer disease must be differentiated from other causes of acute upper gastrointestinal bleeding such as esophageal varices, Mallory-Weiss syndrome, gastrointestinal cancer, arteriovenous malformations, esophagitis, and esophageal ulcer. Peptic ulcer disease must also be differentiated from gastroesophageal reflux disease (GERD,pancreatitis, Zollinger-Ellison Syndrome,cholelithiasis,gastric outlet syndrome,myocardial infaraction ,pleural empyema and appendicitis

Differentiating Peptic Ulcer from other Diseases

Peptic ulcer disease must be differentiated from other diseases that presents with epigastric pain such as gastritis, gastroesophageal reflux disease,acute pancreatitis,prmary biliary cirrhosis,cholelithiasis,gastric outlet syndrome,myocardial infaraction ,pleural empyema,acute appendicitis [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]

Classification of pain in the abdomen based on etiology Disease Clinical manifestations Diagnosis Comments
Symptoms Signs
Fever Rigors and chills Abdominal Pain Jaundice GI Bleed Hypo-

tension

Guarding Rebound Tenderness Bowel sounds Lab Findings Imaging
Abdominal causes Inflammatory causes Pancreato-biliary disorders
Acute pancreatitis + Epigastric ± ± N Increased amylase / lipase Ultrasound shows evidence of inflammation Pain radiation to back
Primary biliary cirrhosis RUQ/Epigastric + N Increased AMA level, abnormal LFTs
Cholelithiasis ± RUQ/Epigastric ± + + N to hyperactive for dislodged stone Leukocytosis Ultrasound shows gallstone Murphy’s sign
Gastric causes Peptic ulcer disease ± EpisodicEpigastric + in perforated + + N
  • Ascitic fluid
    • LDH > serum LDH
    • Glucose < 50mg/dl
    • Total protein > 1g/dl
Air under diaphragm in upright CXR Upper GI endoscopy for diagnosis
Gastritis ± Epigastric + in chronic gastritis
Gastroesophageal reflux disease Epigastric
Gastric outlet obstruction Epigastric ± Hyperactive
Intestinal causes Acute appendicitis + +in pyogenic appendicitis Starts in epigastrium, migrates to RLQ + in perforated appendicitis + + Hypoactive Leukocytosis Ultrasound shows evidence of inflammation Nausea & vomiting, decreased appetite
Extra-abdominal causes Pulmonary disorders Pleural empyema + ± RUQ/Epigastric N
Cardiovascular disorders Myocardial Infarction Epigastric + in cardiogenic shock N
Abbreviations: RUQ= Right upper quadrant of the abdomen, LUQ= Left upper quadrant, LLQ= Left lower quadrant, RLQ= Right lower quadrant, LFT= Liver function test, SIRS= Systemic inflammatory response syndromeERCPEndoscopic retrograde cholangiopancreatographyIV= Intravenous, N= Normal, AMA= Anti mitochondrial antibodies, LDHLactate dehydrogenaseGI= Gastrointestinal, CXR= Chest X ray, IgAImmunoglobulin AIgGImmunoglobulin GIgM=Immunoglobulin MCTComputed tomographyPMN= Polymorphonuclear cells, ESRErythrocyte sedimentation rateCRPC-reactive protein 



Disease Cause Symptoms Diagnosis Other findings
Pain Nausea

&

Vomiting

Heartburn Belching or

Bloating

Weight loss Loss of

Appetite

Stools Endoscopy findings
Location Aggravating Factors Alleviating Factors
Acute gastritis Food Antacids Black stools
Chronic gastritis Food Antacids H. pylori gastritis

Lymphocytic gastritis

  • Enlarged folds
  • Aphthoid erosions
Atrophic gastritis Epigastric pain H. pylori

Autoimmune

Autoimmune gastritis diagnosis include:

Crohn’s disease
  • Mucosal nodularity with cobblestoning
  • Multiple aphthous ulcers
  • Linier or serpiginous ulcerations
  • Thickened antral folds
  • Antral narrowing
  • Hypoperistalsis
  • Duodenal strictures
GERD
  • Lower esophageal sphincter abnormalities
  • Spicy food
  • Tight fitting clothing

(Suspect delayed gastric emptying)

Other symptoms:

Complications

Peptic ulcer disease

Duodenal ulcer

  • Pain aggravates with empty stomach

Gastric ulcer

  • Pain aggravates with food
  • Pain alleviates with food
Gastric ulcers
  • Discrete mucosal lesions with a punched-out smooth ulcer base with whitish fibrinoid base
  • Most ulcers are at the junction of fundus and antrum
  • 0.5-2.5cm

Duodenal ulcers

Other diagnostic tests
Gastrinoma

(suspect gastric outlet obstruction)

Useful in collecting the tissue for biopsy

Diagnostic tests

Gastric Adenocarcinoma Esophagogastroduodenoscopy
  • Multiple biopsies are taken to establish the diagnosis
Other symptoms
Primary gastric lymphoma Useful in collecting the tissue for biopsy Other symptoms

References

  1. Gralnek IM, Barkun AN, Bardou M (2008). “Management of acute bleeding from a peptic ulcer”. N Engl J Med. 359 (9): 928–37. doi:10.1056/NEJMra0706113. PMID 18753649.
  2. Dallal HJ, Palmer KR (2001). “ABC of the upper gastrointestinal tract: Upper gastrointestinal haemorrhage”. BMJ. 323 (7321): 1115–7. PMC 1121602. PMID 11701581.
  3. Nelson DR, Teckman J, Di Bisceglie AM, Brenner DA (2012). “Diagnosis and management of patients with α1-antitrypsin (A1AT) deficiency”. Clin Gastroenterol Hepatol. 10 (6): 575–80. doi:10.1016/j.cgh.2011.12.028. PMC 3360829. PMID 22200689.
  4. Tsochatzis EA, Bosch J, Burroughs AK (2014). “Liver cirrhosis”. Lancet. 383 (9930): 1749–61. doi:10.1016/S0140-6736(14)60121-5. PMID 24480518.
  5. Schuppan D, Afdhal NH (2008). “Liver cirrhosis”. Lancet. 371 (9615): 838–51. doi:10.1016/S0140-6736(08)60383-9. PMC 2271178. PMID 18328931.
  6. Kahrilas PJ (2008). “Clinical practice. Gastroesophageal reflux disease”. N Engl J Med. 359 (16): 1700–7. doi:10.1056/NEJMcp0804684. PMC 3058591. PMID 18923172.
  7. Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM; et al. (2008). “American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease”. Gastroenterology. 135 (4): 1383–1391, 1391.e1–5. doi:10.1053/j.gastro.2008.08.045. PMID 18789939.
  8. Bredenoord AJ, Pandolfino JE, Smout AJ (2013). “Gastro-oesophageal reflux disease”. Lancet. 381 (9881): 1933–42. doi:10.1016/S0140-6736(12)62171-0. PMID 23477993.
  9. Fox M, Forgacs I (2006). “Gastro-oesophageal reflux disease”. BMJ. 332 (7533): 88–93. doi:10.1136/bmj.332.7533.88. PMC 1326932. PMID 16410582.
  10. Sugimachi K, Inokuchi K, Kuwano H, Ooiwa T (1984). “Acute gastritis clinically classified in accordance with data from both upper GI series and endoscopy”. Scand J Gastroenterol. 19 (1): 31–7. PMID 6710074.
  11. Sipponen P, Maaroos HI (2015). “Chronic gastritis”. Scand J Gastroenterol. 50 (6): 657–67. doi:10.3109/00365521.2015.1019918. PMC 4673514. PMID 25901896.
  12. Sartor RB (2006). “Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis”. Nat Clin Pract Gastroenterol Hepatol. 3 (7): 390–407. doi:10.1038/ncpgasthep0528. PMID 16819502.
  13. Sipponen P (1989). “Atrophic gastritis as a premalignant condition”. Ann Med. 21 (4): 287–90. PMID 2789799.
  14. Badillo R, Francis D (2014). “Diagnosis and treatment of gastroesophageal reflux disease”. World J Gastrointest Pharmacol Ther. 5 (3): 105–12. doi:10.4292/wjgpt.v5.i3.105. PMC 4133436. PMID 25133039.
  15. Ramakrishnan K, Salinas RC (2007). “Peptic ulcer disease”. Am Fam Physician. 76 (7): 1005–12. PMID 17956071.
  16. Banasch M, Schmitz F (2007). “Diagnosis and treatment of gastrinoma in the era of proton pump inhibitors”. Wien Klin Wochenschr. 119 (19–20): 573–8. doi:10.1007/s00508-007-0884-2. PMID 17985090.
  17. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM (2005). “Gastric adenocarcinoma: review and considerations for future directions”. Ann Surg. 241 (1): 27–39. PMC 1356843. PMID 15621988.
  18. Ghimire P, Wu GY, Zhu L (2011). “Primary gastrointestinal lymphoma”. World J Gastroenterol. 17 (6): 697–707. doi:10.3748/wjg.v17.i6.697. PMC 3042647. PMID 21390139.

Template:WikiDoc Sources

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

The incidence and prevalence of Helicobacter pylori infection are generally higher among people born outside North America. Within North America, the prevalence of the infection is higher in certain racial and ethnic groups, and people who have immigrated to North America. Peptic ulcer disease is acquired during childhood. The incidence of Peptic ulcer disease increases with age; the median age at diagnosis is 18-30 years. Peptic ulcer disease affects both sexes equally in childhood. Men are more commonly affected by peptic ulcer disease than women in adulthood.

Epidemiology and Demographics

Incidence

Prevalence

Mortality rate

Age

Race

Gender

References

  1. 1.0 1.1 Sung JJ, Kuipers EJ, El-Serag HB (2009). “Systematic review: the global incidence and prevalence of peptic ulcer disease”. Aliment. Pharmacol. Ther. 29 (9): 938–46. doi:10.1111/j.1365-2036.2009.03960.x. PMID 19220208.
  2. Lin KJ, García Rodríguez LA, Hernández-Díaz S (2011). “Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates?”. Pharmacoepidemiol Drug Saf. 20 (7): 718–28. doi:10.1002/pds.2153. PMID 21626606.
  3. Wang AY, Peura DA (2011). “The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world”. Gastrointest. Endosc. Clin. N. Am. 21 (4): 613–35. doi:10.1016/j.giec.2011.07.011. PMID 21944414.
  4. Ohmann C, Imhof M, Ruppert C, Janzik U, Vogt C, Frieling T, Becker K, Neumann F, Faust S, Heiler K, Haas K, Jurisch R, Wenzel EG, Normann S, Bachmann O, Delgadillo J, Seidel F, Franke C, Lüthen R, Yang Q, Reinhold C (2005). “Time-trends in the epidemiology of peptic ulcer bleeding”. Scand. J. Gastroenterol. 40 (8): 914–20. doi:10.1080/00365520510015809. PMID 16165708.
  5. 5.0 5.1 Naja F, Kreiger N, Sullivan T (2007). “Helicobacter pylori infection in Ontario: prevalence and risk factors”. Can. J. Gastroenterol. 21 (8): 501–6. PMC 2657974. PMID 17703249.
  6. Kuipers EJ, Thijs JC, Festen HP (1995). “The prevalence of Helicobacter pylori in peptic ulcer disease”. Aliment. Pharmacol. Ther. 9 Suppl 2: 59–69. PMID 8547530.
  7. Pounder RE, Ng D (1995). “The prevalence of Helicobacter pylori infection in different countries”. Aliment. Pharmacol. Ther. 9 Suppl 2: 33–9. PMID 8547526.
  8. Frenck RW, Clemens J (2003). “Helicobacter in the developing world”. Microbes Infect. 5 (8): 705–13. PMID 12814771.
  9. Dutta AK, Chacko A, Balekuduru A, Sahu MK, Gangadharan SK (2012). “Time trends in epidemiology of peptic ulcer disease in India over two decades”. Indian J Gastroenterol. 31 (3): 111–5. doi:10.1007/s12664-012-0201-5. PMID 22766645.
  10. Goh KL (2009). “Epidemiology of Helicobacter pylori infection in Malaysia–observations in a multiracial Asian population”. Med. J. Malaysia. 64 (3): 187–92. PMID 20527265.
  11. Nguyen T, Ramsey D, Graham D, Shaib Y, Shiota S, Velez M, Cole R, Anand B, Vela M, El-Serag HB (2015). “The Prevalence of Helicobacter pylori Remains High in African American and Hispanic Veterans”. Helicobacter. 20 (4): 305–15. doi:10.1111/hel.12199. PMID 25689684.
  12. Everhart JE, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan G (2000). “Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States”. J. Infect. Dis. 181 (4): 1359–63. doi:10.1086/315384. PMID 10762567.
  13. de Martel C, Parsonnet J (2006). “Helicobacter pylori infection and gender: a meta-analysis of population-based prevalence surveys”. Dig. Dis. Sci. 51 (12): 2292–301. doi:10.1007/s10620-006-9210-5. PMID 17089189.

Template:WH Template:WS

Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: :Manpreet Kaur, MD [2]

Overview

Common risk factors in the development of peptic ulcer disease include infection from Helicobacter pylori, chronic use of NSAIDs, cigarette smoking, alcolhol intake, family history of peptic ulcer, and age >50 years. Less common risk factors in the development of peptic ulcer disease include psychological stress, nosocomial stress ulcers, and coagulopathy. Rare conditions associated with gastric acid hypersecretion, such as zollinger-ellison syndrome, mastocytosis, or a retained antrum following partial gastrectomy, gastrinoma or multiple endocrine neoplasia types I (MEN-I), antral G cell hyperplasia, basophilic leukemias or short bowel syndrome.

Risk Factors

The most potent risk factor leading to the development of peptic ulcer disease is an infection of Helicobacter pylori. Other risk factors include chronic use of NSAIDs, family history of peptic ulcer, tobacco smoking, and psychological and nosocomial stress.[1][2][3][4][5][6][7][8]

Common risk factors

Common risk factors in the development of peptic ulcer disease include:

Less Common Risk Factors

Less common risk factors in the development of peptic ulcer disease include:

References

  1. Huang JQ, Sridhar S, Hunt RH (2002). “Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis”. Lancet. 359 (9300): 14–22. doi:10.1016/S0140-6736(02)07273-2. PMID 11809181.
  2. Ballinger A, Smith G (2001). “COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention”. Expert Opin Pharmacother. 2 (1): 31–40. doi:10.1517/14656566.2.1.31. PMID 11336566.
  3. Holvoet J, Terriere L, Van Hee W, Verbist L, Fierens E, Hautekeete ML (1991). “Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study”. Gut. 32 (7): 730–4. PMC 1378985. PMID 1855677.
  4. Laporte JR, Carné X, Vidal X, Moreno V, Juan J (1991). “Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding”. Lancet. 337 (8733): 85–9. PMID 1670734.
  5. Wachirawat W, Hanucharurnkul S, Suriyawongpaisal P, Boonyapisit S, Levenstein S, Jearanaisilavong J, Atisook K, Boontong T, Theerabutr C (2003). “Stress, but not Helicobacter pylori, is associated with peptic ulcer disease in a Thai population”. J Med Assoc Thai. 86 (7): 672–85. PMID 12948263.
  6. Rosenstock S, Jørgensen T, Bonnevie O, Andersen L (2003). “Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults”. Gut. 52 (2): 186–93. PMC 1774958. PMID 12524398.
  7. Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ (2002). “Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding”. Aliment. Pharmacol. Ther. 16 (3): 497–506. PMID 11876703.
  8. Everhart JE, Byrd-Holt D, Sonnenberg A (1998). “Incidence and risk factors for self-reported peptic ulcer disease in the United States”. Am. J. Epidemiol. 147 (6): 529–36. PMID 9521179.

Template:WikiDoc Sources

Screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

According to the American Society of Gastroenterology, screening for PUD is not recommended.

Screening

According to the American Society of Gastroenterology, screening for PUD is not recommended.

References

Template:WikiDoc Sources

Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

Helicobacter pylori infection is a common cause of peptic ulcer disease which is acquired usually during childhood but presents in second to fifth decade of life. Patient presents with episodic epigastric pain, indigestion, bloating,hematemesis and melena. If not treated, patients can develop complications like bleeding, perforation, obstruction or stricture. Chronic infection of helicobacter pylori leads to gastric cancer, MALT lymphoma, iron deficiency anemia, Idiopathic thrombocytopenic purpura. Peptic ulcers tend to recur if left untreated. Prognosis is good if the eradication therapy of Helicobacter pylori is taken.The recurrence rate of patients with peptic ulcer disease is less than 20%.

Natural History

Complications

Acute complications :

Chronic complications:

Chronic Helicobacter pylori infection leads to:

Prognosis

References

  1. Opekun AR, Gilger MA, Denyes SM, Nirken MH, Philip SP, Osato MS, Malaty HM, Hicks J, Graham DY (2000). “Helicobacter pylori infection in children of Texas”. J. Pediatr. Gastroenterol. Nutr. 31 (4): 405–10. PMID 11045838.
  2. Parkinson AJ, Gold BD, Bulkow L, Wainwright RB, Swaminathan B, Khanna B, Petersen KM, Fitzgerald MA (2000). “High prevalence of Helicobacter pylori in the Alaska native population and association with low serum ferritin levels in young adults”. Clin. Diagn. Lab. Immunol. 7 (6): 885–8. PMC 95979. PMID 11063492.
  3. Malaty HM, El-Kasabany A, Graham DY, Miller CC, Reddy SG, Srinivasan SR, Yamaoka Y, Berenson GS (2002). “Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood”. Lancet. 359 (9310): 931–5. doi:10.1016/S0140-6736(02)08025-X. PMID 11918912.
  4. Kusters JG, van Vliet AH, Kuipers EJ (2006). “Pathogenesis of Helicobacter pylori infection”. Clin. Microbiol. Rev. 19 (3): 449–90. doi:10.1128/CMR.00054-05. PMC 1539101. PMID 16847081.
  5. Milosavljevic T, Kostić-Milosavljević M, Jovanović I, Krstić M (2011). “Complications of peptic ulcer disease”. Dig Dis. 29 (5): 491–3. doi:10.1159/000331517. PMID 22095016.
  6. Cullen DJ, Hawkey GM, Greenwood DC; et al. (1997). “Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs”. Gut. 41 (4): 459–62. PMID 9391242.
  7. “Peptic Ulcer: Peptic Disorders: Merck Manual Home Edition”. Retrieved 2007-10-10.
  8. “Peptic Ulcer: Peptic Disorders: Merck Manual Home Edition”. Retrieved 2007-10-10.

Template:WikiDoc Sources

Diagnosis

History and Symptoms | Physical Examination | Echocardiogram | Laboratory Findings | X Ray | CT | Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Endoscopic management | Surgical management | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case Studies

Case #1

Template:Gastroenterology bs:Ulcerozne lezije želuca ca:Úlcera pèptica da:Mavesår de:Magengeschwür el:Έλκος it:Ulcera peptica nl:Maagzweer no:Magesår nn:Magesår sq:Ulçera në stomak simple:Peptic ulcer fi:Mahahaava sv:Magsår


Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH